Granted Patent B1

US 10,954,289 · App. 17/021,286 · Granted Mar 23, 2021

Inventors: Robert Babb (River Edge, NJ); Alina Baum (Pleasantville, NY); Gang Chen (Yorktown Heights, NY); Cindy Gerson (Irvington, NY); Johanna Hansen (Greenwich, CT); Tammy Huang (Cross River, NY); Christos Kyratsous (Irvington, NY); Wen-Yi Lee (New Hyde Park, NY); Marine Malbec (Port Chester, NY); Andrew Murphy (Croton-on-Hudson, NY); William Olson (Yorktown Heights, NY); Neil Stahl (Carmel, NY); George D. Yancopoulos (Yorktown Heights, NY)

Assignee: Regeneren Pharmaceuticals, Inc.

C07K16/10A61K39/15A61K39/395A61K45/06C07K2317/31C07K2317/52C07K2317/565

Abstract

Claims (28)

1. A vector comprising a polynucleotide encoding a heavy chain variable region (HCVR) of an antibody or antigen-binding fragment thereof that binds a SARS-CoV-2 spike protein comprising the amino acid sequence set forth in SEQ ID NO: 832, wherein said HCVR comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2 and HCDR3), wherein said HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 680, said HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 682, and said HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 684.

2. The vector of claim 1 , wherein said HCVR comprises the amino acid sequence set forth in SEQ ID NO: 678.

3. The vector of claim 1 , wherein said polynucleotide further encodes an immunoglobulin constant region.

4. The vector of claim 3 , wherein said immunoglobulin constant region is an IgG1 constant region.

5. The vector of claim 1 , wherein said polynucleotide encodes a heavy chain amino acid sequence set forth in SEQ ID NO: 692.

6. The vector of claim 1 , wherein said vector is a lentivirus vector.

7. The vector of claim 1 , wherein said vector is an adeno-associated virus vector.

8. The vector of claim 1 , wherein said polynucleotide is a DNA polynucleotide.

9. The vector of claim 1 , wherein said polynucleotide is an RNA polynucleotide.

10. A vector comprising a polynucleotide encoding a light chain variable region (LCVR) of an antibody or antigen-binding fragment thereof that binds a SARS-CoV-2 spike protein comprising the amino acid sequence set forth in SEQ ID NO: 832, wherein said LCVR comprises three light chain complementarity determining regions (CDRs) (LCDR1, LCDR2 and LCDR3), wherein said LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 688, said LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 650, and said LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 690.

11. The vector of claim 10 , wherein said LCVR comprises the amino acid sequence set forth in SEQ ID NO: 686.

12. The vector of claim 10 , wherein said antibody comprises a light chain amino acid sequence set forth in SEQ ID NO: 694.

13. The vector of claim 10 , wherein said vector is a lentivirus vector.

14. The vector of claim 10 , wherein said vector is an adeno-associated virus vector.

15. The vector of claim 10 , wherein said polynucleotide is a DNA polynucleotide.

16. The vector of claim 10 , wherein said polynucleotide is an RNA polynucleotide.

17. A lipid nanoparticle comprising a polynucleotide encoding a heavy chain variable region (HCVR) of an antibody or antigen-binding fragment thereof that binds a SARS-CoV-2 spike protein comprising the amino acid sequence set forth in SEQ ID NO: 832, wherein said HCVR comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2 and HCDR3), wherein said HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 680, said HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 682, and said HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 684.

18. The lipid nanoparticle of claim 17 , wherein said HCVR comprises the amino acid sequence set forth in SEQ ID NO: 678.

19. The lipid nanoparticle of claim 17 , wherein said polynucleotide further encodes an immunoglobulin constant region.

20. The lipid nanoparticle of claim 19 , wherein said immunoglobulin constant region is an IgG1 constant region.

21. The lipid nanoparticle of claim 17 , wherein said polynucleotide encodes a heavy chain amino acid sequence set forth in SEQ ID NO: 692.

22. The lipid nanoparticle of claim 17 , wherein said polynucleotide is a DNA polynucleotide.

23. The lipid nanoparticle of claim 17 , wherein said polynucleotide is an RNA polynucleotide.

24. A lipid nanoparticle comprising a polynucleotide encoding a light chain variable region (LCVR) of an antibody or antigen-binding fragment thereof that binds a SARS-CoV-2 spike protein comprising the amino acid sequence set forth in SEQ ID NO: 832, wherein said LCVR comprises three light chain complementarity determining regions (CDRs) (LCDR1, LCDR2 and LCDR3), wherein said LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 688, said LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 650, and said LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 690.

25. The lipid nanoparticle of claim 24 , wherein said LCVR comprises the amino acid sequence set forth in SEQ ID NO: 686.

26. The lipid nanoparticle of claim 24 , wherein said polynucleotide encodes a light chain amino acid sequence set forth in SEQ ID NO: 694.

27. The lipid nanoparticle of claim 24 , wherein said polynucleotide is a DNA polynucleotide.

28. The lipid nanoparticle of claim 24 , wherein said polynucleotide is an RNA polynucleotide.

Assignments (1)

Continuity (6)

Cited By (13)

US 12,251,440 US 12,257,298 US 12,318,485 US 12,384,811 US 12,459,988 US 12,460,193 US 12,496,470 US 12,508,235 US 12,545,941 US 12,600,764 US 12,607,406 US 12,630,890 US 12,653,880